A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations



Status:Active, not recruiting
Conditions:Lung Cancer, Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/6/2019
Start Date:January 2014
End Date:August 2020

Use our guide to learn which trials are right for you!

Phase 1/2 Study Of Pf-06463922 (an Alk/ros1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-small Cell Lung Cancer Harboring Specific Molecular Alterations

Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported
outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients
and ROS1+ advanced non small cell lung cancer patients .


Inclusion Criteria

- Evidence of histologically or cytologically confirmed diagnosis of metastatic NSCLC
(Stage IV, AJCC v7.0) that carries an ALK rearrangement, as determined by the Food and
Drug Administration (FDA) approved FISH assay (Abbott Molecular Inc) or by
Immunohistochemistry (IHC) (Ventana Inc), or a ROS1 rearrangement as determined by
FISH or RT PCR or Next Generation Sequencing (NGS) via a local diagnostic test (LDT).
All patients (ALK positive and ROS1 positive) must have archival tissue sample
available and collected prior to enrollment.

- Disease Status Requirements:

Phase 1: ALK-positive NSCLC and ROS1-positive patients must either be treatment naïve in
the advanced setting or have had disease progression after at least 1 previous ALK/ROS1
inhibitor therapy(ies).

Phase 2:

ALK-positive NSCLC patients must either be or have had:

- Treatment naïve (ie, no prior chemotherapy in the metastatic disease setting and no
prior ALK inhibitor therapy allowed).

- Disease progression after crizotinib only. No prior chemotherapy is allowed in the
metastatic disease setting.

- Disease progression after crizotinib and 1 or 2 prior regimens of chemotherapy in the
metastatic disease setting.

- Disease progression after 1 prior ALK inhibitor therapy other than crizotinib.
Patients may have had any number of prior chemotherapy regimens in any disease
setting.

- Disease progression after 2 prior ALK inhibitor therapies. Patients may have had any
number of prior chemotherapy regimens in any disease setting.

- Disease progression after 3 prior ALK inhibitor therapies. Patients may have had any
number of prior chemotherapy regimens in any disease setting.

ROS1-positive NSCLC patients may be:

- Treatment naïve (ie, no prior chemotherapy in the metastatic disease setting and no
prior ROS inhibitor therapy).

- Any number of prior therapies (ie, chemotherapy and/or ROS inhibitor therapies).

- Tumor Requirements:

All Patients must have at least one measurable target extracranial lesion according to
RECIST v1.1. In addition patients with asymptomatic CNS metastases (including patients
asymptomatic by means of stable or decreasing doses of steroids within the last 2 weeks
prior to study entry) will be eligible. Patients who have leptomeningeal disease (LM) or
carcinomatous meningitis (CM) are eligible.

- Adequate Bone Marrow, Pancreatic Function, Renal Function and Liver Function.

- Negative Serum pregnancy test for females of childbearing potential Exclusion Criteria

- Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study
entry. Whole brain radiation must have completed at least 4 weeks prior to study
entry.

- Systemic anti cancer therapy completed within a minimum of 5 half lives of study
entry.

- Prior therapy with an antibody or drug specifically targeting T-cell co-stimulation or
immune checkpoint pathways, including, but not limited to, anti-PD-1, anti-PD-L1,
anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4
(anti-CTLA-4) antibody.

- Active and clinically significant bacterial, fungal, or viral infection including
hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or
acquired immunodeficiency syndrome (AIDS) related illness.

- Clinically significant cardiovascular disease (that is, active or <3 months prior to
enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable
angina, congestive heart failure (New York Heart Association Classification Class ≥
II), second-degree or third-degree AV block (unless paced) or any AV block with PR
>220 msec. Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial
fibrillation of any grade, bradycardia defined as <50 bpm (unless patient is otherwise
healthy such as long-distance runners, etc.), machine-read ECG with QTc >470 msec, or
congenital long QT syndrome.

- History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial
fibrosis or interstitial lung disease including a history of pneumonitis,
hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease,
obliterative bronchiolitis and pulmonary fibrosis.

- Current use or anticipated need for food or drugs that are known strong or moderate
CYP3A4 inhibitors, inducers and substrates; drugs that are CYP2C9 substrates; drugs
that are sensitive CYP2B6 substrates; drugs that are strong CYP2C19 inhibitors; drugs
that are strong CYP2C8 inhibitors; and drugs that are P-gp substrates.
We found this trial at
30
sites
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Aurora, Colorado 80045
?
mi
from
Aurora, CO
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Creve Coeur, Missouri 63141
?
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Farmington Hills, Michigan 48334
?
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Fayetteville, Arkansas 72703
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Nashville, Tennessee 37203
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Haven, Connecticut 06504
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New Haven, Connecticut 06520
?
mi
from
New Haven, CT
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
160 East 53rd Street
New York, New York 10022
?
mi
from
New York, NY
Click here to add this to my saved trials
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rochester, New York 14621
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Rogers, Arkansas 72758
?
mi
from
Rogers, AR
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Louis, Missouri 63129
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Sydney Local Health District [RPA], New South Wales
?
mi
from
Sydney Local Health District [RPA],
Click here to add this to my saved trials
750 East Adams Street
Syracuse, New York 13210
?
mi
from
Syracuse, NY
Click here to add this to my saved trials
Washington, District of Columbia 20007
?
mi
from
Washington,
Click here to add this to my saved trials
3800 Reservoir Rd NW
Washington, District of Columbia 20007
(202) 687-7695
Georgetown University Medical Center Georgetown University Medical Center is committed to excellence in research, education...
?
mi
from
Washington,
Click here to add this to my saved trials